Trump Approval Rating Hits All-Time Low Amid Iran War and High Gas Prices

Trump’s Approval Collapse: How Iran, Gas Prices, and Tariffs Are Reshaping Corporate Risk and B2B Strategy

President Trump’s approval ratings have plunged to historic lows—66% disapprove of his handling of the Iran conflict, whereas 76% blame him for surging gas prices at $4.54/gallon, per the latest NPR/PBS News/Marist poll (May 6, 2026). The fiscal fallout is already rippling through energy markets, pharmaceutical trade flows, and midterm election dynamics, forcing corporations to recalibrate risk exposure and supply chain strategies. For executives, the question isn’t *if* these trends will persist—but how to hedge against them.

Three Ways This Crisis Is Redrawing the Boardroom Playbook

• Energy Cost Volatility as a Fiscal Wildcard

  The AAA national average for gasoline has climbed 27 cents in a single week (April 30, 2026), with crude oil hovering above $100/barrel and no resolution in sight for the Strait of Hormuz. For logistics-heavy industries, this isn’t just a consumer issue—it’s a supply chain shock that’s forcing companies to lock in hedging contracts with commodity trading desks or pivot to alternative fuels. The AAA’s latest data shows the national average up 30% year-over-year, a trend that’s squeezing EBITDA margins across transportation, agriculture, and manufacturing.

  

  “We’re seeing clients pre-buy Q3 fuel contracts at 120% of last year’s rates—just to avoid the kind of operational paralysis we saw in 2022.” —Sarah Chen, Managing Director, Risk Advisory Group

  For energy-intensive firms, the solution isn’t just hedging—it’s strategic decarbonization. Companies like BLS data confirms that energy inflation is now the second-largest contributor to CPI (after housing), meaning cost pressures will outlast the election cycle.

• Pharma Tariffs: The Supply Chain Exodus Begins

  Trump’s 100% tariff on patented drugs—effective April 6, 2026—isn’t just a political statement. It’s a trade war escalation with direct consequences for European and Swiss pharma giants. Novartis and Roche’s December 2025 agreements with the U.S. To relocate production are the first dominoes. The Verband Forschender Arzneimittelhersteller (vfa) warns that German and Swiss firms now face a 20-30% cost premium on U.S.-bound exports unless they comply with the new rules. For mid-sized biotech firms, the calculus is brutal: either absorb the tariffs or offshore production entirely.

  This isn’t theoretical. A Marist Poll reveals 44% of Americans now view their cost of living as unaffordable—up from 26% in December 2025. With drug prices a key voter issue, Trump’s tariffs may temporarily boost his base, but the long-term risk is supply chain fragmentation, pushing R&D budgets toward the U.S. At the expense of European innovation hubs.

• The Midterm Election as a Market Stress Test

  The poll’s 63% disapproval of Trump’s economic handling isn’t just noise—it’s a corporate governance wake-up call. Democrats now hold a 7-point midterm edge, per the NPR/Marist data, and control of Congress could accelerate regulatory shifts on trade, climate, and healthcare. For multinational corporations, this means two scenarios:

  1. Scenario 1: Gridlock Persists

     Tariffs stay in place, gas prices remain volatile, and pharma firms accelerate U.S. Production. The winners? Industrial real estate developers in states like Texas and Ohio, where tax incentives are most aggressive.

  2. Scenario 2: Democratic Sweep

     Tariffs are rolled back, but new climate mandates (e.g., carbon border taxes) emerge. Energy firms pivot to renewables, while pharma lobbies for tariff exemptions via the Bureau of Labor Statistics’ inflation-linked adjustments.

  Either way, the strategy playbook is clear: diversify supply chains, lobby for sector-specific relief, and prepare for a 2027 fiscal cliff if tariffs aren’t resolved before the next election.

The B2B Directory Playbook: Who’s Profiting from the Chaos?

This isn’t just a political story—it’s a corporate survival guide. Here’s how firms in our directory are capitalizing:

The Bottom Line: A Fiscal Quarter to Watch

Q3 2026 will be the acid test. If gas prices don’t drop below $4.25/gallon by July, we’ll see:

• A 15-20% surge in demand for energy efficiency audits.
• Pharma firms accelerating U.S. Plant investments—but at the cost of European job losses.
• Midterm polling volatility forcing corporations to double down on lobbying.

The message for executives is clear: This isn’t a temporary blip—it’s a structural shift. The firms that thrive will be those who treat Trump’s approval crisis as a strategic opportunity, not just a political talking point. And the World Today News Directory is where you’ll find the partners to make it happen.